{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:35:54Z","timestamp":1789032954264,"version":"build-2803163510"},"reference-count":60,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Glaukos Corp.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aim<\/jats:title>\n                    <jats:p>While intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma progression, the ultimate goal of glaucoma management is to preserve patients\u2019 functional vision and quality of life. To this end, minimally invasive glaucoma surgeries (MIGSs) aim to reduce IOP with minimal eye trauma. Commonly used MIGS devices include iStent technologies, which have well-documented IOP-reducing potential and favourable safety profiles. However, no study concluded on their effect on the rates of visual field (VF) changes. The aim of this meta-analysis is to determine the long-term effect of iStent technology implantation on glaucoma functional progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Electronic medical literature databases were searched to identify studies reporting on iStent technologies. Reports with follow-up durations &lt;12 months, retention rates &lt;75% and missing VF data were excluded. Fifteen studies reporting on 1115 eyes were identified. The overall weighted mean VF mean deviation (MD) progression, IOP reduction and follow-up duration were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Weighted mean IOP at baseline was 19.0\u00b13.1\u2009mm Hg. At the end of a 37.9-month mean follow-up (range 12\u201396 months), a weighted mean 26.6% IOP reduction was achieved (range 15.2%\u201342.3%). Over the same duration, the weighted mean VF MD progression rate was \u22120.02\u00b10.34 dBs\/year, from a mean baseline of \u22125.76\u00b15.68 dBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this review, which examines functional stability of 1115 eyes, iStent technologies achieved a mean rate of progression of \u22120.024 dBs\/year with serial standard automated perimetry, which is similar to that reported in non-glaucomatous eyes and slower than that reported in medically treated glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001575","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:05:29Z","timestamp":1707998729000},"page":"e001575","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Rates of visual field change and functional progression in glaucoma following trabecular microbypass implantation of iStent technologies: a meta-analysis"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-6253","authenticated-orcid":false,"given":"Kevin","family":"Gillmann","sequence":"first","affiliation":[{"name":"Gen\u00e8ve Ophtalmologie, Geneva, Switzerland"},{"name":"Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M","family":"Hornbeak","sequence":"additional","affiliation":[{"name":"Glaukos Corp, Aliso Viejo, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2025090109420318000_9.1.e001575.1","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.4.2.1","article-title":"Why do people (still) go blind from glaucoma?","volume":"4","author":"Susanna","year":"2015","journal-title":"Transl Vis Sci Technol"},{"key":"2025090109420318000_9.1.e001575.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"2025090109420318000_9.1.e001575.3","doi-asserted-by":"crossref","unstructured":"Epstein R , Seibold L , Ertel M , et al . Microinvasive glaucoma surgery device design considerations. In: Gillmann K , Mansouri K , eds. The Science of Glaucoma Management. Academic Press, 2023: 317\u201327.","DOI":"10.1016\/B978-0-323-88442-6.00022-4"},{"key":"2025090109420318000_9.1.e001575.4","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32834ff1e7"},{"key":"2025090109420318000_9.1.e001575.5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/APO.0000000000000294","article-title":"Minimally invasive glaucoma surgery: where is the evidence?","volume":"9","author":"Gillmann","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2025090109420318000_9.1.e001575.6","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2003.00070.x"},{"key":"2025090109420318000_9.1.e001575.7","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1038\/s41433-023-02532-w","article-title":"Treatment expectations in glaucoma: what matters most to patients?","volume":"37","author":"Safitri","year":"2023","journal-title":"Eye (Lond)"},{"key":"2025090109420318000_9.1.e001575.8","unstructured":"Weinreb RN , Ramulu P , Topouzis F , et al . 11th Consensus Meeting: Glaucoma Surgery. Melbourne: Aus. Kugler Publications, 2019."},{"key":"2025090109420318000_9.1.e001575.9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305550"},{"key":"2025090109420318000_9.1.e001575.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128146","article-title":"iStent as a solo procedure for glaucoma patients: a systematic review and meta-analysis","volume":"10","author":"Malvankar-Mehta","year":"2015","journal-title":"PLoS One"},{"key":"2025090109420318000_9.1.e001575.11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ogla.2018.11.010","article-title":"Aqueous angiographic outflow improvement after trabecular microbypass in glaucoma patients","volume":"2","author":"Huang","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"key":"2025090109420318000_9.1.e001575.12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/j.jcrs.0000000000000325","article-title":"iStent inject: comprehensive review","volume":"47","author":"Shalaby","year":"2021","journal-title":"J Cataract Refract Surg"},{"key":"2025090109420318000_9.1.e001575.13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IJG.0000000000001805","article-title":"Standalone iStent trabecular micro-bypass glaucoma surgery: a systematic review and meta-analysis","volume":"30","author":"Healey","year":"2021","journal-title":"J Glaucoma"},{"key":"2025090109420318000_9.1.e001575.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025090109420318000_9.1.e001575.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2025090109420318000_9.1.e001575.16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/ceo.13763","article-title":"iStent inject trabecular micro-bypass stents with topical prostaglandin as standalone treatment for open-angle glaucoma: 4-year outcomes","volume":"48","author":"Berdahl","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/OPTH.S121041","article-title":"Efficacy of two trabecular micro-bypass stents combined with topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 3-year follow-up","volume":"11","author":"Chang","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.18","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/OPTH.S373290","article-title":"Multicenter effectiveness and disease stability through 3 years after iStentTrabecular micro-bypass with phacoemulsification in glaucoma and ocular hypertension","volume":"16","author":"Clement","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ogla.2019.03.004","article-title":"Five-year, prospective, randomized, multi-surgeon trial of two trabecular bypass stents versus prostaglandin for newly diagnosed open-angle glaucoma","volume":"2","author":"Fechtner","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"key":"2025090109420318000_9.1.e001575.20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/OPTH.S189071","article-title":"Three-year outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic population with primary open-angle glaucoma","volume":"13","author":"Gallardo","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s12325-021-02039-4","article-title":"iStent inject trabecular micro-bypass with or without cataract surgery yields sustained 5-year glaucoma control","volume":"39","author":"Hengerer","year":"2022","journal-title":"Adv Ther"},{"key":"2025090109420318000_9.1.e001575.22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/OPTH.S152268","article-title":"Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes","volume":"12","author":"Katz","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.23","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s12325-016-0420-8","article-title":"Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication: 18-month follow-up","volume":"33","author":"Lindstrom","year":"2016","journal-title":"Adv Ther"},{"key":"2025090109420318000_9.1.e001575.24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40123-019-00208-x","article-title":"Real-world case series of iStent or iStent inject trabecular micro-bypass stents combined with cataract surgery","volume":"8","author":"Manning","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"2025090109420318000_9.1.e001575.25","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.2147\/OPTH.S274281","article-title":"iStent trabecular micro-bypass stent implantation with cataract surgery in a Japanese glaucoma population","volume":"14","author":"Nitta","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/02713683.2020.1795881","article-title":"Five-year outcomes prospective study of two first-generation trabecular micro-bypass stents (iStent\u00ae) in open-angle glaucoma","volume":"46","author":"Saheb","year":"2021","journal-title":"Curr Eye Res"},{"key":"2025090109420318000_9.1.e001575.27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2147\/OPTH.S241628","article-title":"Combined iStent\u00ae Inject trabecular micro-bypass and phacoemulsification in australian patients with open-angle glaucoma","volume":"14","author":"Salby","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40123-020-00266-6","article-title":"Second-generation trabecular micro-bypass (istent inject) with cataract surgery in eyes with normal-tension glaucoma: One-year outcomes of a multi-centre study","volume":"9","author":"Salimi","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"2025090109420318000_9.1.e001575.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40662-021-00263-1","article-title":"Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results","volume":"8","author":"Salimi","year":"2021","journal-title":"Eye Vis (Lond)"},{"key":"2025090109420318000_9.1.e001575.30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2020.12.032","article-title":"Matched cohort study of cataract surgery with and without trabecular microbypass stent implantation in primary angle-closure glaucoma","volume":"224","author":"Salimi","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40123-016-0065-3","article-title":"Newly diagnosed primary open-angle glaucoma randomized to 2 trabecular bypass stents or prostaglandin: Outcomes through 36 months","volume":"5","author":"Vold","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"2025090109420318000_9.1.e001575.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.06.042"},{"key":"2025090109420318000_9.1.e001575.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"2025090109420318000_9.1.e001575.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02492.x"},{"key":"2025090109420318000_9.1.e001575.35","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1111\/aos.12788","article-title":"Progression of visual field in patients with primary open-angle glaucoma - ProgF study 1","volume":"93","author":"Aptel","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/eye.2013.294","article-title":"Portsmouth visual field database: an audit of glaucoma progression","volume":"28","author":"Kirwan","year":"2014","journal-title":"Eye (Lond)"},{"key":"2025090109420318000_9.1.e001575.37","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.72"},{"key":"2025090109420318000_9.1.e001575.38","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1167\/iovs.15-19046","article-title":"Evaluation of glaucoma progression in large-scale clinical data: the Japanese archive of multicentral databases in glaucoma (JAMDIG)","volume":"57","author":"Fujino","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109420318000_9.1.e001575.39","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41433-022-02312-y","article-title":"Effect of trabeculectomy on the rate of progression of visual field damage","volume":"37","author":"Koenig","year":"2023","journal-title":"Eye (Lond)"},{"key":"2025090109420318000_9.1.e001575.40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in glaucoma and ocular hypertension (light) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"},{"key":"2025090109420318000_9.1.e001575.41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/IJG.0000000000001906","article-title":"The association between intraocular pressure and visual field worsening in treated glaucoma patients","volume":"30","author":"Yohannan","year":"2021","journal-title":"J Glaucoma"},{"key":"2025090109420318000_9.1.e001575.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.051"},{"key":"2025090109420318000_9.1.e001575.43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OPTH.S186526","article-title":"Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression","volume":"13","author":"Matlach","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.07.040"},{"key":"2025090109420318000_9.1.e001575.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.035"},{"key":"2025090109420318000_9.1.e001575.46","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/IJG.0000000000001943","article-title":"Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US health care system","volume":"30","author":"Shu","year":"2021","journal-title":"J Glaucoma"},{"key":"2025090109420318000_9.1.e001575.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185246","article-title":"Fluctuation of intraocular pressure in glaucoma patients before and after trabeculectomy with mitomycin C","volume":"12","author":"Wasielica-Poslednik","year":"2017","journal-title":"PLoS One"},{"key":"2025090109420318000_9.1.e001575.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(94)31120-1"},{"key":"2025090109420318000_9.1.e001575.49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"2025090109420318000_9.1.e001575.50","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815c5f4f"},{"key":"2025090109420318000_9.1.e001575.51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40123-020-00290-6","article-title":"Prospective interventional cohort study of ocular surface disease changes in eyes after trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification","volume":"9","author":"Schweitzer","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"2025090109420318000_9.1.e001575.52","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"2025090109420318000_9.1.e001575.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00873-9"},{"key":"2025090109420318000_9.1.e001575.54","first-page":"1419","article-title":"Analysis of progressive change in automated visual fields in glaucoma","volume":"37","author":"Smith","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109420318000_9.1.e001575.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.05.027"},{"key":"2025090109420318000_9.1.e001575.56","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305210"},{"key":"2025090109420318000_9.1.e001575.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.08.006"},{"key":"2025090109420318000_9.1.e001575.58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/IJG.0b013e3181b21fb9","article-title":"Effect of cataract extraction on the glaucoma progression index (GPI) in glaucoma patients","volume":"19","author":"Ang","year":"2010","journal-title":"J Glaucoma"},{"key":"2025090109420318000_9.1.e001575.59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajo.2019.01.019","article-title":"Cataract surgery and rate of visual field progression in primary open-angle glaucoma","volume":"201","author":"Kim","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2025090109420318000_9.1.e001575.60","doi-asserted-by":"crossref","unstructured":"Heatley GA , Nickells RW . Glaucoma pathology. In: Gillmann K , Mansouri K , eds. The Science of Glaucoma Management. Academic Press, 2023: 3\u201315.","DOI":"10.1016\/B978-0-323-88442-6.00018-2"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:42:12Z","timestamp":1756744932000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjophth-2023-001575"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001575","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}